Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4)
GLP-1R agonists were developed as long-acting therapeutic agents to overcome the short half-life of endogenous GLP-1, namely Semaglutide (Ozempic, Wegovy, Rybelsus)
"2022 Prohibited List: Substances and Methods Prohibited at ALL Times (in- And OUT-Of-Competition)" (PDF)
Their smaller body simply burns fewer calories and has less excess weight to lose
More realistic estimate: late 2027, with the drug available at pharmacies in early 2028
Those sets of qRT-PCR probes were as follows: tumor necrosis factor (Tnf, Mm00443260), interleukin 1 beta (Il1b, Mm00434228), interleukin 6 (Il6, Mm00446190), C-C motif chemokine ligand 2 (Ccl2, Mm00441242), stearoyl-CoA desaturase 1 (Scd1, Mm00772290), and fatty acid synthase (Fasn, Mm00662319)